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Abstract
Background: The success of cancer immunotherapies has highlighted the potent ability
of local adaptive immune responses to eradicate cancer cells by targeting neoantigens
generated by somatic alterations. However, how these factors interact to drive the
natural history of muscle-invasive bladder cancer (MIBC) is not well understood.
Objective: To investigate the role of immune regulation in MIBC disease progression, we
performed massively parallel T-cell receptor (TCR) sequencing of tumor-inﬁltrating T
cells (TILs), in silico neoantigen prediction from exome sequences, and expression
analysis of immune-related genes.
Design, setting, and participants: We analyzed 38 MIBC tissues from patients who
underwent deﬁnitive surgery with a minimum clinical follow-up of 2 yr.
Outcome measurements and statistical analysis: Recurrence-free survival (RFS) was
determined. TCR diversity was quantiﬁed using Simpson’s diversity index. The main
analyses involved the Mann-Whitney U test, Kaplan-Meier survival analysis, and Cox
proportional hazards models.
Results and limitations: Low TCRb chain diversity, correlating with oligoclonal TIL
expansion, was signiﬁcantly correlated with longer RFS, even after adjustment for
pathologic tumor stage, node status, and receipt of adjuvant chemotherapy (hazard
ratio 2.67, 95% conﬁdence interval 1.08–6.60; p = 0.03). Patients with both a high
number of neoantigens and low TCRb diversity had longer RFS compared to those with
fewer neoantigens and high TCR diversity (median RFS 275 vs 30 wk; p = 0.03). Higher
expression of immune cytolytic genes was associated with nonrecurrence among
patients with low TCR diversity or fewer neoantigens. Limitations include the sample
size and the inability to distinguish CD8+ and CD4+ T cells using TCR sequencing.
Conclusions: These ﬁndings are the ﬁrst to show that detailed tumor immune-genome
analysis at deﬁnitive surgery can identify molecular patterns of antitumor immune
response contributing to better clinical outcomes in MIBC.
Patient summary: We discovered that clonal expansion of certain T cells in tumor tissue,
possibly targeting cancer-speciﬁc antigens, contributes to prevention of bladder cancer
recurrence.
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Muscle-invasive bladder cancer (MIBC), unlike the more
favorable non–muscle-invasive form (NMIBC), has dismal
prognosis and a high recurrence rate. Extensive genomic
profiling of urothelial cancer suggests that MIBC is driven by
distinct genetic differences from NMIBC [1–5]. In addition,
urothelial carcinoma has a high somatic mutation burden,
third in frequency only after lung cancer and melanoma
[2]. Recent evidence indicates that somatic mutations are the
basis for the generation of potential neoantigens recognized
by antitumor T lymphocytes [6,7], which can be effectively
rescued from an exhausted state by immune checkpoint
blockade therapy in certain patients [8]. Tumor-infiltrating
lymphocytes (TILs) carry prognostic significance in urothelial
cancer, with high CD8 expression in tumors associated with
prolonged disease-free and overall survival [9]. Given these
results, our goal is to improve understanding of the role of
immune regulation in MIBC disease progression. More
specifically, we investigated how potential neoantigens
derived from somatic nonsynonymous mutations influence
the diversity of TILs in MIBC to impact recurrence status and
the length of recurrence-free survival (RFS).
Next-generation sequencing of expressed T-cell receptor
(TCR) transcripts allows for quantification of T-cell diversity
[10,11] via calculation of Simpson’s diversity index (DI)
from sequencing reads, with low DI indicating oligoclonal
T-cell expansion [12]. To comprehensively address correla-
tions between TCR diversity and the mutational neoantigen
landscape of a tumor, we performed TCR sequencing,
whole-exome sequencing with neoepitope prediction, and
immune-related gene expression analysis for 38 chemo-
therapy-naı¨ve MIBC tumors from patients with clinical
follow-up of at least 2 years. To the best of our knowledge,
this in-depth level of integration of the immune and genetic
landscape with clinical outcomes has not been investigated
in MIBC.
2. Materials and methods
2.1. Study design
Under a protocol approved by the University of Chicago institutional
review board (#15550B), tumor tissue and available adjacent normal
frozen tissue were collected from chemotherapy-naı¨ve MIBC patients at
the time of deﬁnitive surgical resection of the primary tumor. Since the
great majority of MIBC patients who experience recurrence (denoted
Rec) will do so within 2 yr, we deﬁned nonrecurrent (NR) patients as
those who were known to be recurrence-free at least 2 yr after deﬁnitive
surgery (median length of follow-up for NR patients 262  59.3 wk;
Supplementary Table 1). We collected all samples with at least 2 yr of
clinical follow-up from the tissue bank organized by one urologist (G.S.). Of
these, we included only tissues that yielded high-quality and sufﬁcient DNA
and RNA after extraction, resulting in a total of 38 cases.
2.2. TCR sequencing
cDNA libraries were prepared using previously described methods
(Supplementary material) [11]. The Bowtie2 aligner was used to map
sequencing reads to the human TCR loci and a previously describedalgorithm was applied to decompose the V-(D)-J regions of the CDR3s
[11]. Simpson’s DI was calculated to quantify the clonality of the TCR a
and b repertoires [12] according to DI ¼ Pi¼1K ni i1ð ÞN N1ð Þ
h i1
, where N is the
total number of sequences, ni is the number of sequences belonging to
the ith clonotype, and K is the total number of clonotypes.
2.3. Assessment of T-cell infiltration
Tumor sections were stained with hematoxylin and eosin, and T-cell
inﬁltration into tumor and stroma was qualitatively assessed by an
attending genitourinary pathologist (T.A.) who was blinded to the TCR DI
scores. All tumors were given a holistic numeric score in comparison to
other samples. After TCR sequencing, a subset of samples with high and
low TCR diversity were also subjected to immunohistochemistry (IHC) for
CD3, CD4, and CD8 to investigate the correlation between T cell number
and DI score. The IHC slides were scored (T.A.) in the same holistic manner.
2.4. Gene expression
Gene expression analysis was performed on tumor cDNAs using TaqMan
gene expression assays (Thermo Fisher Scientiﬁc, Carlsbad, CA, USA)
according to the manufacturer’s instructions. GAPDH (assay
Hs02758991_g1) was used as a housekeeping gene. Ampliﬁcation of
FOXP3 and CD4 within 40 cycles failed for two samples (A18 and A30), so
these were excluded from the analysis.
2.5. Whole-exome sequencing
Libraries were prepared and analyzed as previously described (Supple-
mentary material) [13], with peripheral blood serving as a normal control.
2.6. Bioinformatics analysis
2.6.1. Exome sequencing
Results have already been reported for 28 of the 36 whole-exome
sequencing samples [13]. Eight additional samples were sequenced and
analyzed in the same manner (Supplementary material).
2.6.2. Neoantigen prediction
Neoantigens were predicted for each nonsynonymous variant by deﬁning
all novel 8- to 11-mers resulting from the mutation and determining
whether the predicted binding afﬁnity to human leukocyte antigen (HLA)
class I alleles was <500 nM [14,15] using NetMHCpanv2.8 software
[16,17]. A total of 32 samples underwent neoantigen prediction. Four
samples were excluded owing to unavailability of the HLA type. Two
additional samples lacked normal controls for whole-exome sequencing.
2.7. Statistical analysis
Continuous variables were compared using the Mann-Whitney U test.
Survival analysis was conducted using both Kaplan-Meier log-rank
analysis and Cox proportional hazards models. Analysis was carried out
using GraphPad Prism 6 software (GraphPad, San Diego, CA, USA), and R
version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. TCR sequencing conclusively distinguishes TILs from
normal-tissue T-cell populations
For 20 patients, we performed TCR sequencing on both tumor
and adjacent normal tissues. An attending genitourinary
oncology pathologist (T.A.) verified that tumor tissue
Fig. 1 – T-cell receptor (TCR) sequencing provides granular data on TCR repertoires beyond immunohistochemistry (IHC). (A) Representative heatmaps
of the top 15 clonotypes identified for a and b chains for two samples, comparing tumor (T) and normal (N) distributions. White spaces indicate
particular clonotypes not found in the corresponding tissue. The Supplementary material provides heatmaps for 18 additional samples. Samples were
sorted according to the most abundant clonotypes in each chain and compared to corresponding tumor or normal tissue. Unique clonotypes found in
tumor tissue were absent or hardly detectable (frequency <0.1%) in corresponding normal tissue for most samples. (B) Representative IHC examples
for CD8 in muscle-invasive bladder cancer tumors with high TCR diversity. Tumor A4 (DI 95.3) has minimal CD8 staining in tumor and stroma, while
tumor A6 (DI 120.6) has moderate staining in tumor and minimal staining in stroma. (C) CD8 staining of two tumors with low TCR diversity. Tumor
A24 (DI 11.6) has minimal staining in tumor and stroma, while tumor A9 (DI 10.5) has minimal tumor staining and moderate stromal staining. TCR DI
scores did not correlate with qualitative scoring of T-cell infiltration according to IHC (performed by a pathologist blinded to DI scores). DI = Simpson’s
diversity index.
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tissue excluded tumor cells. Analysis of V-(D)-J combinations
with complementarity-determining region 3 (CDR3)
sequences demonstrated that unique TCR clonotypes in
tumor tissues were absent or hardly detectable in the
adjacent normal tissues (frequency <0.01; Fig. 1A and
Supplementary Fig. 1). We concluded that the tumor TCR
repertoires were significantly different from those of
adjacent normal tissues, and then focused our TCR analysis
only on tumor tissue for the remaining 18 patients because of
our interest in TIL diversity.
TCR sequencing was performed on a total of 38 tumors
(Table 1, Supplementary Table 1). To assess whether the
number of T cells influences DI quantification, we per-
formed IHC for CD3, CD4, and CD8 on a subset of samples
(Fig. 1B and Supplementary Fig. 2). A pathologist blinded to
the sample DIs independently and qualitatively scored the
degree of T-cell infiltration into tumor centers and the
surrounding stroma. We observed that even patients with
very low DI values (DI <10) had varying degrees of T-cell
infiltration into tumor centers and surrounding stroma,
ensuring that these low DI scores were not simply due to
low TIL numbers. Since it was noted that high-DI samples
(DI >50) also had similar variations in TIL numbers, DI is
truly a representation of the clonal expansion of T cells and
not simply a reflection of the total number of T cells.3.2. TCR diversity in primary tumors foreshadows recurrence
risk
Notably, we observed that tumors from NR patients had a
lower TCRb DI than tumors from Rec patients (mean 
standard deviation [SD] 36.1  31.8 vs 129.8  159; p = 0.08,
Fig. 2A). We pursued this finding by classifying tumors into
binary DI groups using the median DI as a cut-point. Kaplan-
Meier survival analysis revealed that patients with low TCRb
DI had significantly longer RFS than patients with high TCRb
DI (median not reached vs 34.7 wk; log-rank test p = 0.018,
Fig. 2B and Supplementary Fig. 3). The relationship between
RFS and TCRb DI remained significant after adjusting for
pathologic tumor stage, node status, and receipt of adjuvant
chemotherapy in a Cox proportional hazards model (p = 0.033,
hazard ratio [HR] 2.67, 95% confidence interval [CI] 1.08–
6.60). We also stratified patients according to tumor stage/
node status and observed a positive correlation between DI
and tumor stage/node status when assessed without other
covariates (analysis of variance p = 0.028; Fig. 2C). These
results indicate that primary tumors at a more advanced
pathologic stage at the time of surgery already have less
oligoclonal T cell expansion.
We hypothesized that in Rec patients with low TCRb DI,
immunosuppressive regulatory T (Treg) cells rather than
cytolytic CD8+ T cells may be expanding. We therefore
Table 1 – Patient demographic data: detailed clinical variables associated with prognosis in the 38 patients with muscle-invasive bladder
cancer included in the study
Patient Rec Time to Gender Age at pT pN Histology Site of recurrence Adjuvant
ID FU or surgery therapy
Rec (wk) (yr)
A3 Y 6.1 F 72 pT4a pN0 Adenocarcinoma Pulmonary nodules,
gastric masses
N
A4 Y 23.1 M 70 pT3b pN0 UC Iliac masses N
A10 Y 30.0 M 65 pT3b pN1 UC Bone Y
A11 Y 36.9 F 74 pT3a pN0 UC Pulmonary nodules N
A14 Y 5.4 M 59 pT4a pN2 UC Liver, lungs, LN, bone Y
A15 Y 29.4 M 57 pT3a pN1 UC with sarcomatoid
features
Pelvic mass and LN Y
A18 Y 188.1 M 77 pT2a pN0 UC Pelvic mass, liver N
A20 Y 27.0 M 50 pT3b pN0 UC Pelvic mass, LN Y
A24 Y 48.7 M 45 pT4a pN1 UC RP LN Y
A25 Y 86.6 M 70 pT4a pN2 UC with small-cell or
NE features
Pelvic LN, brain Y
A26 Y 68.4 F 78 pT3a pN1 UC Bone N
A27 Y 62.3 M 70 pT4a pN2 UC Bone, pelvic LN Y
A28 Y 39.3 M 68 pT4a pN2 UC Pelvic mass and LN Y
A29 Y 9.7 F 80 pT4a pN2 UC Lungs, mediastinum,
hila, liver, RP LN
N
A30 Y 12.3 M 49 pT4a pN2 Adenocarcinoma Bowel N
A32 Y 22.4 M 76 pT3b pN2 SCC Pelvic mass,
periportal LN
N
A34 Y 138.1 M 62 pT3a pN2 UC RP LN Y
A36 Y 16.9 M 68 pT3a pN1 UC Unspeciﬁed sites Y
A37 Y 25.1 M 70 pT3b pN0 UC Pulmonary nodules N
A38 Y 3.6 M 59 pT4 pN0 SCC Pelvic, lower
abdominal LN
N
A1 N 360.6 M 78 pT3b pN0 SCC NA N
A2 N 287.1 M 57 pT2b pN0 UC with squamous
features
NA N
A5 N 261.7 M 67 pT2b pN0 UC NA N
A6 N 262.6 F 68 pT3a pN0 UC NA N
A7 N 347.7 M 74 pT4a pN0 UC NA N
A8 N 239.0 F 60 pT3a pN0 UC with squamous
features
NA N
A9 N 166.6 F 43 pT2b pN0 UC with squamous
features
NA N
A12 N 265.4 M 59 pT2b pN0 UC NA N
A13 N 234.1 M 55 pT3a pN0 UC NA N
A16 N 220.4 M 84 pT3a pN0 UC NA N
A17 N 71.9 M 68 pT2a pN0 UC NA N
A19 N 289.7 F 74 pT2b pN2 UC NA Y
A21 N 249.1 M 39 pT3a pN0 UC NA Y
A22 N 330.9 M 57 pT2a pN0 UC NA N
A23 N 209.6 M 56 pT3a pN0 UC NA N
A31 N 212.6 M 78 pT3a pN1 UC with squamous
features
NA N
A33 N 378.3 M 74 pT3a pN1 UC NA Y
A35 N 323.7 M 52 pT3b pN1 UC NA Y
REC = recurrence; FU = follow-up; M = male; F = female; pT = pathologic primary tumor stage; pN = pathologic node status as deﬁned by the American Joint
Committee on Cancer; UC = urothelial carcinoma; NE = neuroendocrine; SCC = squamous cell carcinoma; RP = retroperitoneal; LN = lymph node; Y = yes;
N = no; NA = not applicable.
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expression using median expression in all tumors (equal to
3.9) as the cut-point. Among Rec patients, those with lower
TCR DI scores typically also had low CD8/FOXP3 expression,
although the difference was not statistically significant
(Supplementary Fig. 4A). More interestingly, we observed a
significantly positive correlation between CD8/FOXP3 ex-
pression and DI among Rec patients that was not seen in NR
patients (R2 = 0.57; p < 0.001, Supplementary Fig. 4B).
These two observations indicate that Rec patients withlow T-cell diversity may have dominant expansion of
certain Treg cells and, similarly, Rec patients with high CD8/
FOXP3 ratios may lack clonal expansion of antitumor CD8+ T
cells, as evidenced by their comparatively higher TCRb DI
values.
3.3. Predicted neoantigens impact on clinical outcome
Whole-exome sequencing of 36 of the 38 MIBC tumors
revealed a higher somatic non-synonymous mutation
Fig. 2 – Low T-cell receptor (TCR) diversity index (DI) correlates with clinical outcome. (A) Patients without disease recurrence (NR; n = 17) had lower
average TCR b DI compared to patients who experienced recurrence (Rec; n = 21) (36.1 W 31.8 vs 129.8 W 159, p = 0.08). (B) Kaplan-Meier curve of RFS,
with patients divided into groups with high and low TCR DI groups (median DI 40.4; p value by log-rank test). (C) Stratification according to tumor
size and nodal status (p value by analysis of variance).
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been validated in other tumor types (mean  SD
217  152 vs 103.4  94; p = 0.007, Supplementary Fig. 5).
We performed in silico potential neoantigen or neoepitope
prediction from these nonsynonymous mutations [8,18,19]
for 32 of our 38 MIBC tumors (Supplementary Tables 2 and 3).
The number of somatic nonsynonymous mutations had a
tightly linear positive correlation with the number of
predicted neoantigens (R2 = 0.89; p < 0.0001, Supplementary
Fig. 6). Tumors from NR patients had a higher average number
of predicted neoantigens (177.8 vs 103.9; p = 0.032, Fig. 3A).
To ensure we selected only those neoantigens most likely to be
presented to T-cells, we applied two additional filtering
criteria: (1) HLA-binding affinity of >500 nM for the
corresponding wild-type peptide; and (2) affinity at least
three times greater for the mutant than for the wild-type
peptide (larger numbers indicate weaker affinity). The
relationship between filtered neoantigen load and RFS was
not statistically significant (median RFS not reached vs
52.6 wk for high vs low neoantigen group; log-rank
p = 0.11, Fig. 3B). We next compared the relationship between
filtered neoantigen load and DI, and observed that there was
no relationship between neoantigen load and TCR diversity
(p = 0.9) in the NR group, but a positive correlation in the Rec
group (p = 0.07), with a statistically significant difference in
slope between the two cohorts (p = 0.038; Fig. 3C). This
indicates that NR tumors maintain low TCR diversity
independent of the number of predicted neoantigens, while
in Rec tumors TCR diversity simply increases in the presence
of more neoantigens.Finally, we compared RFS using stratification according
to both neoantigen load and TCRb diversity. Patients with a
high neoantigen load and low TCRb diversity had longer RFS
compared to those with low neoantigen load and high TCR
diversity (median RFS 275 vs 30 wk; p = 0.03, Supplemen-
tary Fig. 7).
3.4. Immune-related gene expression signature differentiates
clinical outcome
We performed gene expression assays for CD4, CD8, FOXP3,
indoleamine 2,3-dioxygenase 1 (IDO1), granzyme A (GZMA),
and perforin-1 (PRF1). High expression of CD8, GZMA, and
PRF1 is associated with an immunostimulatory profile,
while high expression of CD4, FOXP3, and IDO1 is associated
with immunoregulation. For each of these factors, we
calculated the NR/Rec expression ratio. We found that NR
tumors had higher levels of CD8/CD4 expression (p < 0.01,
Table 2). Among tumors with either low DI or low
neoantigen load, NR patients had significantly higher levels
of CD8, CD8/CD4, GZMA, and IDO1 compared to Rec patients
(Fig. 4A). For visual representation, we generated a heatmap
of immunostimulatory gene expression according to
recurrence, diversity, and neoantigen classification (Fig.
4B). Of note, there was a highly linear positive correlation
between CD8 and IDO1 expression (R2 = 0.82, p < 0.001);
IDO1 expression is probably upregulated in response to CD8
upregulation in a negative feedback mechanism [20,21].
These data suggest that a degree of both intratumoral
oligoclonal T-cell expansion and high expression of
Fig. 3 – A combination of a high number of neoantigens and low T-cell receptor (TCR) diversity index (DI) mediates survival and nonrecurrence.
(A) Tumors from patients without recurrence (NR) had a higher number of predicted neoantigens than tumors from patients who experience
recurrence (Rec; 177.8 vs 103.9; p = 0.032). (B) Kaplan-Meier survival analysis reveals a nonsignificant recurrence-free survival (RFS) benefit for
patients with tumors with a high number of predicted neoantigens (RFS median not reached vs 52.6 wk for high vs low neoantigens; p = 0.11). (C)
Tumors from NR patients exhibit no association between neoantigen number and TCR DI (p = 0.9), while there is a positive correlation for Rec patients
(p = 0.07). The difference in slope is significant (p = 0.038).
Table 2 – Expression ratios for immunocytolytic genes according to clinical outcome a
All patients Low diversity Lower NNA High diversity Higher NNA
(n = 36) (n = 17) (n = 13) (n = 19) (n = 16)
NR/Rec p value NR/Rec p value NR/Rec p value NR/Rec p value NR/Rec p value
CD8 2.97 0.342 11.85 0.06 10.55 0.029 1.90 0.898 0.75 1
CD8/CD4 2.17 0.003 4.52 0.027 6.96 0.007 1.60 0.179 0.70 0.562
GZMA 10.22 0.071 26.12 0.027 41.99 0.019 4.90 0.416 2.10 0.635
IDO1 27.62 0.077 57.17 0.048 149.86 0.019 2.00 0.373 2.10 0.679
CD8/FOXP3 1.43 0.232 2.42 0.45 3.35 0.029 1.50 0.21 0.70 0.635
NNA = number of neoantigens; NR/Rec = expression ratio between patients without recurrence (NR) and patients with recurrence (Rec).
a Expression levels of the genes listed in the table differed signiﬁcantly by clinical outcome according to genetic and diversity variables. In samples with low
diversity, relative increases in CD8, GZMA, and IDO1 expression were observed in tumors from Rec patients. Similar trends are seen for tumors with fewer than
the median number of neoantigens (low neoantigen load). These trends were not seen for tumors with high diversity or those with high numbers of neoantigens.
The Mann-Whitney U test was used to determine p values.
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against recurrence.
4. Discussion
Our study is the first to examine the relationship between
predicted neoantigen load and TCR diversity with clinical
outcomes in chemotherapy-naı¨ve MIBC. No study has
quantitatively characterized the TIL receptor repertoire in
depth via TCR sequencing in MIBC. Our results demon-
strate that DI is a measure of the expansion of T cells
that captures the functionality of TILs in a manner that
cannot be achieved with IHC quantification alone. TCRsequencing may therefore more objectively capture the
immune environment within the entire tumor sample
and be a novel method for predicting disease course in
MIBC.
The finding that TCR DI remains associated with RFS
even after correcting for prognostic clinical variables
implies that it is the immune response to genetic (and
epigenetic) alterations, rather than simply the genetic
alterations themselves, that influences clinical outcome. As
evidence, TCR DI was associated with RFS, but neoantigen
load alone was not. Such a hypothesis is validated by a
recent trial demonstrating a strong clinical response to
anti-PDL1 therapy in MIBC [22]. Just as boosting the
Fig. 4 – Patients without recurrence (NR) exhibit higher levels of immunocytolytic gene expression than patients who experienced recurrence (Rec)
when stratified by diversity and neoantigen load. (A) For each group indicated, we calculated the relative expression of CD8, CD8/CD4, GZMA, and CD8/
FOXP3 for tumors from NR patients over Rec patients. T-cell populations with high CD8/FOXP3 expression have high ratios of cytolytic CD8+ T cells to
Treg cells, while T-cell populations with a low CD8/FOXP3 expression ratio correspond to a low CD8+ T cell to Treg ratio. Bars marked with asterisks
reached statistical significance (p < 0.05). The difference in immunocytolytic gene expression is greatest for tumors with a low number of predicted
neoantigens (n = 5 NR, n = 9 Rec). In calculating the NR/Rec gene expression ratio, we used the standard error of the mean to represent error bars.
HD = high diversity; LD = low diversity; HNa = high neoantigen load; LNa = low neoantigen load. (B) Heatmap of gene expression of immune-related
factors according to recurrence status, TCR diversity, and neoantigen classification. Red indicates the highest expression and green indicates the
lowest. The scale is normalized for each gene. NR tumors with low diversity tended to have higher expression of immunostimulatory factors and
IDO1. H = high; L = low.
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improvement in MIBC, our study shows that patients
who intrinsically have more robust intratumoral immune
responses independently have improved long-term
clinical outcomes. Patients with low TCR DI at the time
of cystectomy may therefore be optimal candidates for
immunotherapy.
The lack of correlation between RFS and neoantigen load
also suggests that while a higher mutation burden increases
the likelihood of generating relevant neoantigens [8], NR
tumors may simply have ‘‘won the neoepitope lottery’’ to
generate those few true neoantigens that elicit strong
oligoclonal T-cell expansion, probably via high-affinity
binding to both TCR and HLA class I molecules [23]. In
other words, having a greater number of neoantigens
increases the probability, but without guarantee, of
capturing those strongly immunogenic neoantigens capable
of stimulating a very effective antitumor immune response.
T-cell anergy may also contribute to the inability of Rec
tumors to mount an effective immune response to
presented neoantigens. Assessment of PD1 or PDL1 may
therefore clarify the relationship between TCR DI and
neoantigen load. In the interim, identification of potential
critical neoantigens in MIBC, or those already capable ofinducing strong T cell–mediated responses, could poten-
tially serve as a basis for peptide vaccines.
The limitations of our study include its small sample size,
making it critical to validate the results by analyzing future
MIBC patient cohorts with appropriate clinical follow-up to
improve our understanding of these relationships. Second,
variant tumor histology is a potential confounder in our
analysis that could not be corrected. Third, our TCR
sequencing approach cannot distinguish subsets of T cells;
however, flow cytometry cannot be used to perform these
analyses owing to the limited availability of cancer tissues
and technical difficulty in separating subsets of cells in solid
tumors. Finally, next-generation sequencing does not allow
definition of the TCR a and b pair that recognizes
neoantigens. Single-cell sequencing, by contrast, could
potentially help to identify the pair of TCR chains that
respond to neoantigens.
5. Conclusions
Taken together, our results have important implications for
prognostic prediction in MIBC, as well as for the future use
of immunotherapies. In particular, identification of the
neoepitopes capable of stimulating oligoclonal T-cell
E U R O P E A N U R O L O G Y F O C U S 2 ( 2 0 1 6 ) 4 4 5 – 4 5 2452expansion could offer new avenues for adaptive T-cell
therapy and peptide vaccines for various types of human
tumor by either boosting the natural antitumor system or
by compensating for deficiencies in genetic alterations. Our
results demonstrate that integration of the genetic and
immune landscapes of bladder tumors provides valuable
prognostic information on the clinical course of MIBC that
can be harnessed for therapeutic measures.
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